Please sign John Olver and Dana Rohrabacher's Congressional Sign-on letter to
the Drug Enforcement Administration in support of Professor Lyle Craker's
application for a Schedule I license to produce research-grade marijuana for
FDA- and DEA-approved clinical studies at the University of Massachusetts.

It is hypocritical for DEA on the one hand to cite insufficient research as a
reason for keeping marijuana un-prescribable, while on the other hand preventing
the very research that it says is needed from taking place.  Professor Craker's
proposal would end this catch-22 that the DEA has created, by allowing the
controversy over medical marijuana's safety and efficacy to be settled through
FDA-approved clinical trials.